CA3130751A1 - New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine - Google Patents
New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine Download PDFInfo
- Publication number
- CA3130751A1 CA3130751A1 CA3130751A CA3130751A CA3130751A1 CA 3130751 A1 CA3130751 A1 CA 3130751A1 CA 3130751 A CA3130751 A CA 3130751A CA 3130751 A CA3130751 A CA 3130751A CA 3130751 A1 CA3130751 A1 CA 3130751A1
- Authority
- CA
- Canada
- Prior art keywords
- dao
- specifically
- recombinant
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03022—Diamine oxidase (1.4.3.22)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/20—Sequence assembly
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B35/10—Design of libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Library & Information Science (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19157932.5 | 2019-02-19 | ||
| EP19157932 | 2019-02-19 | ||
| PCT/EP2020/054197 WO2020169577A1 (en) | 2019-02-19 | 2020-02-18 | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3130751A1 true CA3130751A1 (en) | 2020-08-27 |
Family
ID=65493995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3130751A Pending CA3130751A1 (en) | 2019-02-19 | 2020-02-18 | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220145269A1 (enExample) |
| EP (1) | EP3927817B1 (enExample) |
| JP (1) | JP7792252B2 (enExample) |
| KR (1) | KR20210132650A (enExample) |
| CN (1) | CN113785052B (enExample) |
| AU (1) | AU2020225319B2 (enExample) |
| BR (1) | BR112021015865A2 (enExample) |
| CA (1) | CA3130751A1 (enExample) |
| EA (1) | EA202192305A1 (enExample) |
| ES (1) | ES3041133T3 (enExample) |
| IL (1) | IL285452B2 (enExample) |
| MX (1) | MX2021010050A (enExample) |
| SG (1) | SG11202107659SA (enExample) |
| WO (1) | WO2020169577A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| WO2022072718A1 (en) | 2020-09-30 | 2022-04-07 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| EP4496488A4 (en) * | 2022-03-21 | 2025-11-26 | Cedars Sinai Medical Center | METHODS AND COMPOSITIONS FOR THE SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE INTESTINAL MICROBIOME |
| IL317379A (en) * | 2022-06-03 | 2025-02-01 | Oyster Point Pharma Inc | AAV vector encoding diamine oxidase and its uses |
| EP4782002A1 (en) * | 2025-01-27 | 2026-07-29 | DR Healthcare S.L.U. | Diamine oxidase (dao) for use in the treatment of infertility |
| CN121975758B (zh) * | 2026-04-02 | 2026-07-14 | 华中科技大学同济医学院附属同济医院 | 组胺氧化酶蛋白及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK402785D0 (da) * | 1985-09-03 | 1985-09-03 | Syn Tek Ab | Fremgangsmaade til fremstilling af et enzym |
| US6075007A (en) * | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| IT1317067B1 (it) * | 2000-11-29 | 2003-05-26 | Univ Roma | Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico. |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| CA2536016C (en) * | 2002-08-16 | 2017-01-10 | Paul L. Deangelis | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same |
| US20050255114A1 (en) * | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| AT502098B8 (de) * | 2004-07-07 | 2007-06-15 | Albert Dr Missbichler | Diaminooxidase-hältige zusammensetzung |
| CA2660286A1 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| WO2012028891A1 (en) * | 2010-09-02 | 2012-03-08 | Debreceni Egyetem | Perorally applicable preparation containing histaminase of vegetable origin, resistant to pepsin and trypsin and a process for producing it |
| JP2014518632A (ja) * | 2011-06-01 | 2014-08-07 | モアハウス スクール オブ メディスン | ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法 |
| AU2015332533B2 (en) * | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| WO2023122254A2 (en) * | 2021-12-22 | 2023-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to elicit desire to mate and mating behavior |
-
2020
- 2020-02-18 JP JP2021548232A patent/JP7792252B2/ja active Active
- 2020-02-18 WO PCT/EP2020/054197 patent/WO2020169577A1/en not_active Ceased
- 2020-02-18 CA CA3130751A patent/CA3130751A1/en active Pending
- 2020-02-18 SG SG11202107659SA patent/SG11202107659SA/en unknown
- 2020-02-18 AU AU2020225319A patent/AU2020225319B2/en active Active
- 2020-02-18 BR BR112021015865-0A patent/BR112021015865A2/pt unknown
- 2020-02-18 CN CN202080020112.7A patent/CN113785052B/zh active Active
- 2020-02-18 EP EP20704547.7A patent/EP3927817B1/en active Active
- 2020-02-18 US US17/430,714 patent/US20220145269A1/en active Pending
- 2020-02-18 ES ES20704547T patent/ES3041133T3/es active Active
- 2020-02-18 MX MX2021010050A patent/MX2021010050A/es unknown
- 2020-02-18 EA EA202192305A patent/EA202192305A1/ru unknown
- 2020-02-18 IL IL285452A patent/IL285452B2/en unknown
- 2020-02-18 KR KR1020217024580A patent/KR20210132650A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3041133T3 (en) | 2025-11-07 |
| EP3927817C0 (en) | 2025-08-20 |
| AU2020225319B2 (en) | 2025-05-29 |
| KR20210132650A (ko) | 2021-11-04 |
| US20220145269A1 (en) | 2022-05-12 |
| BR112021015865A2 (pt) | 2021-10-05 |
| SG11202107659SA (en) | 2021-09-29 |
| WO2020169577A1 (en) | 2020-08-27 |
| EP3927817B1 (en) | 2025-08-20 |
| CN113785052A (zh) | 2021-12-10 |
| IL285452B2 (en) | 2025-07-01 |
| CN113785052B (zh) | 2024-06-28 |
| IL285452A (en) | 2021-09-30 |
| MX2021010050A (es) | 2021-09-21 |
| JP2022520862A (ja) | 2022-04-01 |
| EP3927817A1 (en) | 2021-12-29 |
| AU2020225319A1 (en) | 2021-10-14 |
| IL285452B1 (en) | 2025-03-01 |
| JP7792252B2 (ja) | 2025-12-25 |
| EA202192305A1 (ru) | 2021-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3927817B1 (en) | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine | |
| US11697678B2 (en) | Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof | |
| US20200040051A1 (en) | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose | |
| JP2019059768A (ja) | ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素 | |
| KR102569907B1 (ko) | 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법 | |
| CN106573966A (zh) | 用于治疗代谢异常的组合物和方法 | |
| ES3037618T3 (en) | Proteins with diagnostic and therapeutic uses | |
| JP2018517726A (ja) | 老化関連症状を治療するための方法および組成物 | |
| US20160237133A1 (en) | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use | |
| US20170291931A1 (en) | Fgf2 truncations and mutants and uses thereof | |
| US20190276510A1 (en) | Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemia | |
| EP3491011A1 (en) | Fibroblast growth factor (fgf) 1 proteins with glucose lowering ability and reduced mitogenicity | |
| JP7736749B2 (ja) | アミノ酸枯渇治療のための組成物の使用方法 | |
| US10414808B2 (en) | Huwentoxin-IV variants and methods of use | |
| EP4133067A1 (en) | An enzyme | |
| US20230097335A1 (en) | Fibroblast growth factor 1 (fgf1) mutant proteins that selectively activate fgfr1b to reduce blood glucose | |
| HK40064258A (en) | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine | |
| US6893844B1 (en) | DNA encoding a new human hepatoma derived growth factor and producing method thereof | |
| HK40064258B (en) | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine | |
| WO2014014819A2 (en) | Methods of treating glucose metabolism disorders | |
| EP3144007A1 (en) | Peptide for use in the treatment of disease caused by clostridium neurotoxins | |
| NZ790135A (en) | Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof | |
| WO2014014816A2 (en) | Methods of treating glucose metabolism disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231227 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250211 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250211 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250211 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250314 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250314 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250425 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250425 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250609 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250930 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251127 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260209 |